Annual report pursuant to Section 13 and 15(d)

Segment Information (Schedule of Segment Information) (Details)

v3.22.1
Segment Information (Schedule of Segment Information) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Segment Reporting Information [Line Items]    
Net Revenue $ 68,791 $ 45,599
Direct cost of goods (32,084) (14,594)
Research and development (128,865) (64,109)
Selling, general and administrative 86,843 61,166
Wire transfer fraud loss (9,540)  
Other expense 24,188 (8,579)
Income tax expense (473) (136)
Net loss (164,826) (102,985)
Dermatology Products Sales [Member]    
Segment Reporting Information [Line Items]    
Net Revenue 63,134 44,531
Direct cost of goods (32,084) (14,594)
Research and development (16,558)  
Selling, general and administrative 39,895 22,100
Wire transfer fraud loss (9,540)  
Other expense (7,479) (697)
Income tax expense 0 (96)
Net loss (42,422) 7,044
Pharmaceutical and Biotechnology Product Development [Member]    
Segment Reporting Information [Line Items]    
Net Revenue 5,657 1,068
Direct cost of goods 0 0
Research and development (112,307) (64,109)
Selling, general and administrative 46,948 39,066
Wire transfer fraud loss 0  
Other expense 31,667 (7,882)
Income tax expense (473) (40)
Net loss $ (122,404) $ (110,029)